Cutaneous adverse reactions are common during anti-tumor therapy, which not only greatly affect patients′ quality of life, but may also cause discontinuation and dose reduction of anti-tumor therapy. With the increasing diversity of anti-tumor drugs, cutaneous adverse reactions have become more complex and challenging for clinicians. In view of this, the Shanghai Society of Dermatology and Venereology and Shanghai Society of Target Molecular Oncology, Shanghai Medical Association organized experts to discuss and sort out existing relevant clinical evidence to develop an expert consensus. This consensus summarizes cutaneous adverse reactions to anti-tumor drugs, such as cytotoxic chemotherapy drugs, molecular targeted drugs, and immune checkpoint inhibitors, and proposes prevention and management measures for common cutaneous adverse reactions, aiming to provide standardized guidance for clinicians and nurses in the fields of oncology and dermatology in clinical practice.

Antineoplastic agents; Drug toxicity; Skin adverse reactions; Management strategies; Consensus